Monday June 26th 2017

‘Tech’ Archives

Prof. Dake’s presentation on CCSVI part 1

Prof. Dake’s presentation on CCSVI part 1

Prof. Dake gives a presentation at the annual meeting of interventional radiologists about stenting jugular veins for MS. The presentations can be watched on a webcast: hosted.mediasite.com Posted by Sam Daniels [Read More]

CCSVI As Cause of Multiple Sclerosis

CCSVI As Cause of Multiple Sclerosis

Images from my diagnostic MRV showing jugular stenosis, and corrective stents/angioplasty. More at healingpowernow.com Posted by Mark [Read More]

Helen Yates of MSRC discusses MS & CCSVI

Helen Yates of MSRC discusses MS & CCSVI

Helen Yates, Chief Executive of MSRC discusses MS and Chronic Cerebrospinal Venous Insufficiency – CCSVI on BBC Radio Essex. Posted by Harris Luis [Read More]

 Page 1 of 5  1  2  3  4  5 »

Latest Topics

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

BACKGROUND: In people with Multiple Sclerosis (pwMS), balance assessment is essential in estimating the risk of falls, [Read More]

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

The European Medicines Agency ’ s Committee for Medicinal Products for Human Use recommends approval of cladribine to [Read More]

Germany’s Merck gets EU backing for oral MS drug

Germany’s Merck gets EU backing for oral MS drug

FRANKFURT (Reuters) - Germany's Merck KGaA has won a key recommendation to become a late entrant to the market for oral [Read More]

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

Roche announced today that new post-hoc analyses from the OCREVUS ™ (ocrelizumab) Phase III clinical trial programme [Read More]

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

/About-the-Society/News/Society-Hosts-Joint-Congressional-Briefing-on-the [Read More]